Novaremed AG, a privately held clinical-stage biopharmaceutical company, is innovating chronic pain management through the development of effective and safe treatment options as an alternative to opioids. HQ Basel (Switzerland); subsidiaries Novaremed Ltd (Israel) & Metys Pharmaceuticals (CH).
Products, services, technology
NRD.E1, a novel orally active non-opioid small molecule, is in NIH-sponsored Phase 2b study to treat painful diabetic peripheral neuropathy (PDPN). MP-101 (Phase 2) studied for prevention of chemotherapy-induced peripheral neuropathy (CIPN); MP-103 (preclin) for CIPN & other peripheral neuropathies.
Novaremed is interested in potential partnership with pharmaceutical companies for Phase 3 development and commercialisation of its lead compound, NRD.E1.